950 Winter Street
About Radius HealthRadius is a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases.
Radius is committed to the research and development of new therapeutics for the large and underserved osteoporosis market.
October 3, 2003
Founders: John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts
CEO: Robert Ward
CMO (Medical): Lorraine Fitzpatrick
CFO: Nick Harvey
CSO (Scientific): Gary Hattersley
Please click here for Radius Health job opportunities.
Please click here for clinical trial information.
188 articles with Radius Health
Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Hoeiland, President and CEO of the Company, will present a corporate update at the Jefferies 2019 Global Healthcare Conference in London, United Kingdom on Wednesday, November 20, 2019 at 6:00 p.m. GMT.
TYMLOS U.S. net sales grew to $47M and is capturing half of anabolic new patient starts
Radius Health to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 5, 2019
Radius Health announced that it will release its third quarter 2019 financial results on Tuesday, November 5, 2019.
Charles Morris, chief medical officer for Waltham, Mass.-based Radius Health, is eying the day that there will be better outcomes for breast cancer patients who have developed tumors resistant to current treatments. If things continue to go well, Radius may be able to provide those options.
Radius Health Provides Updates on its Oncology Programs and Announces Scientific Presentations at 2018 San Antonio Breast Cancer Symposium (SABCS)
• Phase 3 elacestrant study has opened for enrollment • Fast Track designation from the FDA for the Phase 3 study population • Elacestrant pre-clinical data demonstrates further evidence of anti-tumor activity in breast cancer models with resistance to CDK 4/6 inhibitors and in models harboring ESR1 mutations resistant to standard of care therapies • RAD140 Phase 1 study continues to enroll patients with further evaluation of the maximum tolerated dose
Radius Health Announces Latest 2019 Medicare Part D Coverage for TYMLOS® (abaloparatide) InjectionTYMLOS is now covered for 64% of Medicare Part D insured lives
Radius Health, Inc. today announced the latest 2019 Medicare Part D coverage for TYMLOS which increased to approximately 26.2 million lives or 64% of those enrolled in Medicare Part D plans in the U.S.
9/10/2018Let's take a look at who made a splash in the pharma and biotech world the past week.
Radius Health to Announce Fourth Quarter and Full Year 2017 Financial Results, Host Conference Call and Live Webcast on March 1, 2018
The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the results and provide a company update.
Ms. Webb is a CFA charterholder and joins Radius from Genfit Corporation where she was Vice President and Head of Investor Relations.
Radius Health Announces that the CHMP Will Issue a Third Day-180 List of Outstanding Issues in its Regulatory Review of Abaloparatide-SC
Radius Health now anticipates an opinion from the CHMP regarding the MAA for abaloparatide-SC in the first half of 2018.
Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
Elacestrant recently received Fast Track designation from the U.S. Food and Drug Administration.
The stock option vests 25% on the first anniversary of the grant date, with the remaining 75% to vest in monthly installments over the three years thereafter, and has a ten-year term.
Radius Health Announces Commercial Leadership Changes with Appointment of Joseph Kelly as Senior Vice President of Sales and Marketing, and Promotion of Amanda Mott to Senior Vice President of Market Access
Mr. Kelly succeeds David Snow who served as the Company’s Chief Commercial Officer since 2015 and is leaving Radius.
Radius Health Reports Third Quarter 2017 Financial and Operating Results and Provides Business Update
Third quarter reported sales of TYMLOS in the U.S. (the first full quarter since its launch) were approximately $3.5 million.
Radius plans to initiate Phase 2 clinical study of elacestrant as a third-line therapy for women with ER+ and HER2- breast cancer early in 2018.
Radius Health To Announce Third Quarter 2017 Financial Results, Host Conference Call And Live Webcast On November 2, 2017
Radius Health Initiates Phase I Clinical Trial Of RAD140 For The Treatment Of Hormone Receptor Positive Breast Cancer
Radius Health Presents Positive Data For TYMLOS (Abaloparatide) Injection From The Activextend Trial At ASBMR 2017 Annual Meeting
Radius Health Announces Proposed Public Offering Of $300 Million Of Convertible Senior Notes Due 2024